Abstract:Fragile X syndrome is an inheritable form of intellectual disability caused by loss of fragile X mental retardation protein (FMRP, encoded by the FMR1 gene). Absence of FMRP caused overexpression of progranulin (PGRN, encoded by GRN), a putative tumour necrosis factor receptor ligand. In the present study, we found that progranulin mRNA and protein were upregulated in the medial prefrontal cortex of Fmr1 knock-out mice. In Fmr1 knock-out mice, elevated progranulin caused insufficient dendritic spine pruning and late-phase long-term potentiation in the medial prefrontal cortex of Fmr1 knock-out mice. Partial progranulin knock-down restored spine morphology and reversed behavioural deficits, including impaired fear memory, hyperactivity, and motor inflexibility in Fmr1 knock-out mice. Progranulin increased levels of phosphorylated glutamate ionotropic receptor GluA1 and nuclear factor kappa B in cultured wild-type neurons. Tumour necrosis factor receptor 2 antibody perfusion blocked the effects of progranulin on GluA1 phosphorylation; this result indicates that tumour necrosis factor receptor 2 is required for progranulin-mediated GluA1 phosphorylation and late-phase long-term potentiation expression. However, high basal level of progranulin in Fmr1 knock-out mice prevented further facilitation of synaptic plasticity by exogenous progranulin. Partial downregulation of progranulin or tumour necrosis factor receptor 2/nuclear factor kappa B signalling restored synaptic plasticity and memory deficits in Fmr1 knock-out mice. These findings suggest that elevated PGRN is linked to cognitive deficits of fragile X syndrome, and the progranulin/tumour necrosis factor receptor 2 signalling pathway may be a putative therapeutic target for improving cognitive deficits in fragile X syndrome.

The FAM171A2 gene is a key regulator of progranulin expression and modifies the risk of multiple neurodegenerative diseases

The <i>FAM171A2</i> gene is a key regulator of progranulin expression and modifies the risk of multiple neurodegenerative diseases

Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis

Elevated Progranulin Contributes to Synaptic and Learning Deficit Due to Loss of Fragile X Mental Retardation Protein.

Pathogenic cysteine mutations affect progranulin function and production of mature granulins.

Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease.

Progranulin mutations as risk factors for Alzheimer disease

Progranulin as a therapeutic target in neurodegenerative diseases

Targeted sequencing on neurodegenerative genes identified novel causal and risk variants of familial Alzheimer's disease

Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases

Progranulin Protects Against Amyloid Β Deposition and Toxicity in Alzheimer’s Disease Mouse Models

Progranulin Gene Mutations in Chinese Patients with Frontotemporal Dementia: A Case Report and Literature Review

Single-cell multimodal analysis in a case with reduced penetrance of Progranulin-Frontotemporal Dementia

Ftd-Psp Is An Unusual Clinical Phenotype In A Frontotemporal Dementia Patient With A Novel Progranulin Mutation

A case of familial frontotemporal dementia caused by a progranulin gene mutation

Exaggerated Inflammation, Impaired Host Defense, and Neuropathology in Progranulin-Deficient Mice

Losing protein in the brain: the case of progranulin

Association of Rare Variants in Neurodegenerative Genes with Familial Alzheimer's Disease.

Author Correction: FAM222A Encodes a Protein Which Accumulates in Plaques in Alzheimer’s Disease

Structure, Function, and Mechanism of Progranulin; the Brain and Beyond

Co-existence of multiple functional variants and genes underlie genetic risk locus 11p11.2 of Alzheimer's disease